Consequently, androgen deprivation therapy (ADT), which diminishes circulating testosterone levels and blocks cellular AR signaling via surgical or chemical castration, remains the cornerstone of treatment for prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.